Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809960 | 0.83 | ALDH1A1 (1.00) | MAPTALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL4483341 | 0.81 | MAPT (0.66) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3196920 | 0.80 | MAPT (0.56) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6536307 | 0.79 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL31665889 | 0.79 | PIK3CA (0.69) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL802630 | 0.78 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2729559 | 0.78 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL12821529 | 0.76 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29329864 | 0.76 | ALDH1A1 (0.48) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10925574 | 0.75 | MAPT (0.85) | MAPTALDH1A1SMN1; SMN2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| EP-4561556-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024236367-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-11-21 | — | — | WO | disclosed |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-05-02 | — | — | US | disclosed |
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284781-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | Vandria SA (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20220259173-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | SPIROCHEM AG (CH) | 2022-08-18 | — | — | US | disclosed |
| WO-2022162471-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | VANDRIA SA (CH) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UBQLN2, SOD1, UBQLN1 | MAPT 114/4885ALDH1A1 1601/4885SMN1; SMN2 8/4885 |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAPT 217/4885ALDH1A1 851/4885SMN1; SMN2 179/4885 |
| US-20220259173-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | MAPT 217/4885ALDH1A1 851/4885SMN1; SMN2 179/4885 |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | MAPT 217/4885ALDH1A1 851/4885SMN1; SMN2 179/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAPT 217/4885ALDH1A1 851/4885SMN1; SMN2 179/4885 |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | TNNT2, TNNI3, TNNC1 | MAPT 1139/4885ALDH1A1 747/4885SMN1; SMN2 200/4885 |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAPT 217/4885ALDH1A1 851/4885SMN1; SMN2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.